Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Mind Medicine (MindMed) Inc
N.MMED.WR
Primary Symbol:
MNMD
Alternate Symbol(s):
N.MMED.WS
|
N.MMED.WA
|
N.MMED
Healthcare
Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen...
drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:MNMD)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
(231)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Nov 07, 2024 4:45pm
MindMed Reports Third Quarter 2024 Financial Results and Bus
News; $MNMD MindMed Reports Third Quarter 2024 Financial Results and Business Updates--On track to initiate the Phase 3 Voyage study of MM120 Orally Disintegrating Tablet (ODT) in Generalized Anxiety
...more
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Jun 28, 2024 7:01am
New Press Release - MindMed to be Included in Russell 2000® and Russell 3000® Indexes
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced today that as part of the annual reconstitution of the Russell stock indexes, the Company will...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Jun 21, 2024 7:00am
New Press Release - MindMed to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that members of the Company’s management team will present at the H.C. Wainwright 5th Annual...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Jun 20, 2024 7:02am
New Press Release - MindMed Announces Constructive End-of-Phase 2 Meeting with U.S. FDA for MM120 in Generalized Anxiety Disorder (GAD)
-Aligned on requirements for Phase 3 clinical development of MM120 for the treatment of GAD--Initiation of Phase 3 program remains on schedule to begin in second half of 2024- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company...
read article.
(2)
•••
Robert1999
X
View Profile
View Bullboard History
Comment by
Robert1999
on Jun 06, 2024 8:27pm
RE:RE:RE:Stock Price Pressure
49.12% % of Shares Held by Institutions 50.47% % of Float Held by Institutions 161 Number of Institutions Holding Shares % was 5%, 1 month ago...very promising
(80)
•••
Starkicker
X
View Profile
View Bullboard History
Comment by
Starkicker
on Jun 06, 2024 12:00pm
RE:Stock Price Pressure
This doesn't look great. PTSD treatment was kind of MM's thing. https://www.forbes.com/sites/roberthart/2024/06/05/psychedelic-stocks-tank-after-fda-advisors-shoot-down-mdma-therapy-for-ptsd/
...more
(263)
•••
sollmg
X
View Profile
View Bullboard History
Comment by
sollmg
on Jun 05, 2024 11:40am
RE:RE:Stock Price Pressure
Further searching found this on seeking alpha https://seekingalpha.com/news/4113189-rbc-recommends-buying-mindmed-amid-psychedelic-stocks-sell-off RBC recommends buying MindMed amid psychedelic
...more
(2)
•••
Robert1999
X
View Profile
View Bullboard History
Comment by
Robert1999
on Jun 05, 2024 11:21am
RE:Stock Price Pressure
100% agree It's not the time to sell
(263)
•••
sollmg
X
View Profile
View Bullboard History
Post by
sollmg
on Jun 05, 2024 10:24am
Stock Price Pressure
I looked for news to try and find a reason for the price movement. Found nothing bad. Then looked at the shorts. 22% of the float short. looks like a bear attack. Also looked at the institutional
...more
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on May 04, 2024 8:01am
New Press Release - MindMed Presents Phase 2b Study of MM120 for Generalized Anxiety Disorder (GAD) at American Psychiatric Association (APA) Annual Meeting in New York
-A single oral administration of MM120 100 µg met its primary and key secondary endpoints and maintained clinically and statistically significant HAM-A reductions compared to placebo at 12 weeks with a 65% clinical response rate and a 48% clinical remission rate--MindMed also presents two new...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on May 02, 2024 7:08am
New Press Release - MindMed to Host Conference Call and Webcast to Discuss First Quarter 2024 Financial Results and Provide Business Update
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it plans to host a conference call on Wednesday, May 8, 2024, at 4:30 p.m. ET to provide a...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Apr 25, 2024 7:02am
New Press Release - MindMed to Present at Upcoming May Medical Conferences
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it will present detailed results from its phase 2b study of MM120 in Generalized Anxiety...
read article.
(80)
•••
Starkicker
X
View Profile
View Bullboard History
Comment by
Starkicker
on Apr 12, 2024 3:06pm
RE:mmed
You might have to call your broker to request a transfer to NSDQ otjerwise the shares will show up in your account but the values won't and you won't be able to trade them. Only takes one to
...more
(80)
•••
Starkicker
X
View Profile
View Bullboard History
Comment by
Starkicker
on Apr 06, 2024 9:11am
RE:mmed
They'll just get transferred. You'll still own the same amount. Your account will probably show in USD though.
(0)
•••
dave1100
X
View Profile
View Bullboard History
Post by
dave1100
on Apr 04, 2024 3:06pm
mmed
What will happen to my Canadian shares once MMED is only on the nasdaq?
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >